Results
intermittent self-injuring behaviors
REMISSION, SECONDARY, PATHOLOGY
Between December 20 2020 and September 30 2021 we recruited 33 patients, of these 9 (27.27%) were excluded due to either not meeting the inclusion criteria (3/33, 9.09%), declining to participate once asked to sign the informed consent form (5/33, 15.15%), or moving to another city (1/33, 3.03%). The remaining 24 patients were randomly allocated (see Fig. Eight (8/24, 33.33%) persons reported unintended effects, including the four that dropped out. Four patients (including 2 that dropped out) in CG experienced low-to-moderate side effects during the antipsychotic medication (C3, C10, C2, and C9). One (C9) also reported intermittent self-injuring behaviors between the end of the first month and the beginning of the fifth month. Three other patients showed self-injuring behaviors in the first two months of the intervention, and then remitted, 1 from EG (E5) and 2 from CG (C1 and C8). As reported, one patient in the EG (E3) had a BPE and was excluded from the study to receive medication.No significant differences between the two arms were found at baseline (tMean personality pathology across measurements. Group-by-time interaction effect on primary outcomeWe report the test (sphericity assumed) of within-subjects effects. Table The secondary outcomes reported mixed results at 1-month follow-up. OR did not show significant differences in rate of remission from SPD between the two groups (OR = 3.667; C.I. = 0.323–41.590; χGroup-by-time interaction effect on secondary outcomesWe report the test (sphericity assumed) of within-subjects effects. Tables Changes in symptomatology and metacognition. Finally, the whole sample showed a high rate of completion (83.33%) and significant differences between initial and follow-up assessment for all the measures (η